Vanda Pharmaceuticals
Open
$5.90
Prev. Close
$5.90
High
$5.91
Low
$5.85
Market Snapshot
$346.96M
-1.4
-0.33
$198.77M
533
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The firm's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 533 full-time employees. The company went IPO on 2006-04-12. The firm's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Recently from Cashu
Vanda Pharmaceuticals Calls for Better FDA Guidance on Animal Testing Alternatives
Vanda Pharmaceuticals Advocates For Improved FDA Guidance on Animal Testing Alternatives Vanda Pharmaceuticals Inc., a prominent player in the realm of innovative drug development, expresses grave con…
Vanda Pharmaceuticals Challenges FDA Draft Guidance on Ethical Drug Development Practices
Vanda Pharmaceuticals Voices Concerns Over FDA's New Draft Guidance on Drug Development Vanda Pharmaceuticals Inc., a prominent player in innovative drug development, recently raises serious objection…
Vanda Pharmaceuticals Gains Rare FDA Hearing for HETLIOZ® Treatment of Jet Lag Disorder
Vanda Pharmaceuticals Secures Rare FDA Hearing for HETLIOZ® on Jet Lag Disorder Vanda Pharmaceuticals Inc. faces a significant regulatory milestone as the U.S. Food and Drug Administration (FDA) grant…
Vanda Pharmaceuticals Hosts FDA Hearing for HETLIOZ® Jet Lag Treatment Approval
Vanda Pharmaceuticals Seeks Clarity in Jet Lag Treatment Approval Process Vanda Pharmaceuticals Inc. achieves a significant procedural milestone as the U.S. Food and Drug Administration (FDA) grants i…